Rosario Notaro
Florence, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy.
Journal: HemaSphere
Published: February 06, 2026
Prophylaxis and management of thromboembolism in pnh patients: an italian survey.
Journal: Annals of hematology
Published: February 03, 2026
PNH extravascular hemolysis: exploring clinical significance.
Journal: Blood advances
Published: December 05, 2025
ETV4 and ETV1-mediated downregulation of the secretory leukocyte protease inhibitor contributes to the indolent phenotype of early-stage prostate cancer.
Journal: Biochimica et biophysica acta. Molecular basis of disease
Published: February 13, 2025
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.
Journal: The Lancet. Haematology
Published: January 13, 2025
Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complement inhibitor to anti-C5 therapy: A lesson not to be forgotten.
Journal: American journal of hematology
Published: August 15, 2024
Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.
Journal: Annals of hematology
Published: July 16, 2024
Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
Journal: The New England journal of medicine
Published: March 13, 2024
The inhibition of several components of terminal complement pathway results in C3 binding to PNH red blood cells.
Journal: American journal of hematology
Published: November 27, 2023
Last Updated: 09/26/2026